Effect of amifostine (Ethyol®) on the development of extraembryonic blood vessels in chick embryos

Strahlentherapie und Onkologie

Volumn 175, Issue 1, 1999, Pages 28-31

  Höper, Jens ^a,d   Hanjalic, Aida ^b   Sauer, Rolf ^c   Plasswilm, Ludwig ^a  

^a Institut für Physiologie und Kardiologie Und   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Amifostine; Angiogenesis

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CAPILLARY DENSITY; CELL PROTECTION; CHICK EMBRYO; CONTROLLED STUDY; DEPHOSPHORYLATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; NONHUMAN;

EID: 17044458579     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02743458     Document Type: Article

References (26)

1. Calabro-Jones PM, Aguilera JA, Ward JF. Uptake of Wr-2721 derivatives by cells in culture: Identification of the transported form of the drug. Cancer Res 1988;48:3634-40.
2. Calabro-Jones PM, Aguilera JA, Ward JF, et al. The limits to radioprotection of Chinese hamster V79 cells by WR-1065 under areobie conditions. Radiat Res 199S; 149:550-9.
3. Davidson DE, Grenan MM, Sweeney TR. Biological characteristics of some improved radioprotectors. In: Brady LW, ed. Radiation sensitizers: Their use in clinical management of cancer. New York: Masson, 1980:309.
4. Dorr, RT, Lagel, KE. Anthracycline cardioprotection by amifostine (WR-2721) and its active metabolite in vitro. Proc Am Soc Clin Oncol 1994; 13:435.abstract.
5. Fahey RC. HPLC analysis of thiols using monobromobimane fluorescent labeling: Applications to radioprotective drugs. In: Miquel J, Quintanilha A, Weber H, eds. Handbook of biomedicine of free radicals and antioxidants. Boca Raton, Fla.: CRC Press, 1989:265-70.
6. Höper J. Influence of local oxygen deficiency on function and integrity of liver, kidney and heart. Stuttgart: Fischer, 1991.
7. Höper J, Jahn H. Influence of environmental oxygen concentration on growth and vascular density of the area vasculosa in chick embryos. Int J Microcirc 1995;15:186-92.
8. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatmcnt for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101-12.
9. Liu T, Liu Y, He S. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992;69:2820-5.
10. McDonald S, Meyerowitz C, Smudzin T, et al. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck produce salivary gland dysfunction. Int J Radial Oncol Biol Phys 1994;29:747-54.
11. Millar JL, McEIwain TJ, Clutterbruck RD. The modification of melphalan toxicity in tumor-bearing mice by S-2[3-aminopropylamino]ethylphophorothioic acid (WR-2721). Am J Clin Oncol 1982;5:321-8.
12. Ohinsi ST, Ohinsi T, Click JH, et al. In vitro study on the antioxidant activities of amifostine (WR-2721). Proc Am Assoc Cancer Res 1992;33:419. abstract 2503.
13. Paine G, Taylor CW, Lopez MHA. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma in xenografts in the severe combined immune-deficient mouse: preliminary results. Semin Oncol 1996;23:Suppl 8:35-9.
14. Patt HM, Tyree EB, Straube RL, et al. Cysteine protection against X irradiation. Science 1949;110:213-4.
15. Plasswilm L, Höper J. Radiobiologische In-vivo-Untersuchung zur Angiogenese am Dottersackgefäßsystem des Hühnerembryos. Strahlenther Onkol 1996:172:260-4.
16. Romanul FCA, Bannister RG. Localized areas of high alkaline phosphatase activity in endothelium of arteries. Nature 1962:195:611-2.
17. Rubin, DB, Drab, EA, Rang, HJ, et al. WR-1065 and radioprotection of vascular cndothelial cells. I. Cell proliferation, DNA synthesis and damage. Radiat Res 1996;145:210-6.
18. Shaw LM, Bonner HS, Turrisi A, et al. A liquid Chromatographie electrochemical assay for S-2[3-aminopropylamino]ethylphophorothioate (WR-2721) in human plasma. J Liq Chromatogr 1984:7:2447-65.
19. Smoluk GD, Fahey RC, Calabro-Jones PM. Radioprotection of cells in culture by WR-2721 and derivates: Form of the drug responsible for protection. Cancer Res 19S8;48:3641-7.
20. Speicher LA, Krutzsh M, Wymer J, et al. Amifostine does not inhibit the cytotoxic effect of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. Proc Am Assoc Cancer Res 1995;36:290.abstract 1727.
21. Trcskes M, Boven E, Holwcrdea U. Time dependence of selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse. Cancer Res 1992:52:2257-60.
22. Treskes M, Boven E, Loosdrecht AA. Effects of the modulating agent WR-2721 on myelotoxicity and antitumor activity in carboplatin-treated mice. Eur J Cancer 1994:30:183-7.
23. Yang JL, Fernandes DJ, Speicher L. Biochemical determinants of the cytoprotective effect of amifostine. Proc Am Assoc Cancer Res 1995;36: 290.abbtract 1725.
24. Yuhas JM, Spellman JM, Cuo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 19SO;3:211-6.
25. Yuhas JM, Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 1980:64:57-64.
26. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2[3-aminopropylamino]ethylphophorothioic acid. Cancer Res 1980;40:1519-24.